This session ONLY has been solely funded by AbbVie UK. AbbVie has selected the speaker & content of the agenda, AbbVie products will be discussed
QUICK DIVE: Endometriosis: Hormonal Management Update (Manchester)
This meeting has been organised by CliniLink Ltd and is supported through sponsorship which covers the costs of exhibition stands. The sponsors Exeltis, Gedeon Richter and Theramex were not involved in the development of the agenda and have had no influence over the agenda, the speakers or the content of the meeting.
The symposium session only has been solely funded by AbbVie UK. AbbVie has selected the speaker and the content of the session. AbbVie products will be discussed
See Sponsors below

£0.00
FACE TO FACE EVENT
THIS EVENT IS OPEN TO UK REGISTERED HEALTHCARE PROFESSIONALS ONLY
Location: Royal Nawaab Stockport Pyramid, Yew Street
Event Agenda
| Time | Topic | Speaker |
|---|---|---|
| 6:30 - 7:00 | Registration, Networking and Coffee | |
| 7:00 - 7:45 | Migraine: Impact, diagnosis and management approaches and Use of AQUIPTA® (atogepant) for the prophylactic management of episodic migraine This session ONLY has been solely funded by AbbVie UK. AbbVie has selected the speaker & content of the agenda, AbbVie products will be discussed | Dr Razaan Haneef – GPwER Migraine |
| 7:45 - 8:45 | Established hormonal options in endometriosis CHC, POP, LNG-IUS and GnRH agonists Choosing therapy based on symptoms, fertility goals, side-effect profile, and long-term management Newer and emerging treatments Targeted progesterone therapies Oral GnRH antagonist combination therapies | Ajay Swaminathan |
| 8:45 - 9:00 | Q&A & Dinner |
Why Should Healthcare Professionals Attend
Endometriosis: Hormonal Management Update
This CPD-accredited, face-to-face study day provides UK healthcare professionals with a practical, evidence-based update on the hormonal management of endometriosis.
Led by Mr Ajay Swaminathan, the session covers both established and emerging hormonal therapies, supporting clinicians to make confident, individualised treatment decisions based on symptoms, fertility goals, side-effect profiles, and long-term management needs.
Key Learning Outcomes
-
Review established hormonal options, including CHC, POP, LNG-IUS, and GnRH agonists
-
Learn how to tailor treatment to patient symptoms, reproductive plans, and tolerability
-
Understand newer and emerging therapies, including targeted progestogen therapies and oral GnRH antagonist combination therapies
-
Apply evidence-based guidance to real-world clinical practice
All attendees will receive a CPD certificate for full participation.
